BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $22.98 billion. The enterprise value is $7.53 billion.
| Market Cap | 22.98B |
| Enterprise Value | 7.53B |
Important Dates
The next estimated earnings date is Monday, August 3, 2026, before market open.
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 252.88 million shares outstanding. The number of shares has increased by 1.91% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 252.88M |
| Shares Change (YoY) | +1.91% |
| Shares Change (QoQ) | +3.81% |
| Owned by Insiders (%) | 16.25% |
| Owned by Institutions (%) | 20.14% |
| Float | 110.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.11 |
| Forward PS | 10.57 |
| PB Ratio | 1.07 |
| P/TBV Ratio | 1.19 |
| P/FCF Ratio | 31.70 |
| P/OCF Ratio | 24.44 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 10.39 |
Financial Position
The company has a current ratio of 8.80, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.80 |
| Quick Ratio | 8.11 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.48 |
| Interest Coverage | -97.41 |
Financial Efficiency
Return on equity (ROE) is -6.66% and return on invested capital (ROIC) is -25.58%.
| Return on Equity (ROE) | -6.66% |
| Return on Assets (ROA) | -4.18% |
| Return on Invested Capital (ROIC) | -25.58% |
| Return on Capital Employed (ROCE) | -7.31% |
| Weighted Average Cost of Capital (WACC) | 11.42% |
| Revenue Per Employee | $414,296 |
| Profits Per Employee | -$184,935 |
| Employee Count | 7,807 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.34 |
Taxes
In the past 12 months, BioNTech SE has paid $90.74 million in taxes.
| Income Tax | 90.74M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.41% in the last 52 weeks. The beta is 1.32, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | -13.41% |
| 50-Day Moving Average | 94.83 |
| 200-Day Moving Average | 99.56 |
| Relative Strength Index (RSI) | 49.42 |
| Average Volume (20 Days) | 1,068,226 |
Short Selling Information
The latest short interest is 2.26 million, so 3.30% of the outstanding shares have been sold short.
| Short Interest | 2.26M |
| Short Previous Month | 2.45M |
| Short % of Shares Out | 3.30% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.42 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $3.23 billion and -$1.44 billion in losses. Loss per share was -$5.89.
| Revenue | 3.23B |
| Gross Profit | 2.54B |
| Operating Income | -1.63B |
| Pretax Income | -1.35B |
| Net Income | -1.44B |
| EBITDA | -1.37B |
| EBIT | -1.63B |
| Loss Per Share | -$5.89 |
Balance Sheet
The company has $15.80 billion in cash and $349.13 million in debt, with a net cash position of $15.45 billion or $61.11 per share.
| Cash & Cash Equivalents | 15.80B |
| Total Debt | 349.13M |
| Net Cash | 15.45B |
| Net Cash Per Share | $61.11 |
| Equity (Book Value) | 21.56B |
| Book Value Per Share | 85.25 |
| Working Capital | 15.87B |
Cash Flow
In the last 12 months, operating cash flow was $940.51 million and capital expenditures -$211.00 million, giving a free cash flow of $724.97 million.
| Operating Cash Flow | 940.51M |
| Capital Expenditures | -211.00M |
| Depreciation & Amortization | 253.35M |
| Net Borrowing | -12.26M |
| Free Cash Flow | 724.97M |
| FCF Per Share | $2.87 |
Margins
Gross margin is 78.65%, with operating and profit margins of -50.35% and -44.64%.
| Gross Margin | 78.65% |
| Operating Margin | -50.35% |
| Pretax Margin | -41.83% |
| Profit Margin | -44.64% |
| EBITDA Margin | -42.47% |
| EBIT Margin | -50.35% |
| FCF Margin | 22.41% |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.91% |
| Shareholder Yield | n/a |
| Earnings Yield | -6.28% |
| FCF Yield | 3.15% |
Analyst Forecast
The average price target for BioNTech SE is $122.32, which is 35.58% higher than the current price. The consensus rating is "Buy".
| Price Target | $122.32 |
| Price Target Difference | 35.58% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | -4.21% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 7.3 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.3 |
| Piotroski F-Score | 3 |